HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by ADAMS, M. R. Articles by PARKS, J. S. Search for Related Content PubMed PubMed Citation Articles by ADAMS, M. R. Articles by PARKS, J. S.

Low-Dose Contraceptive Estrogen-Progestin and Coronary Artery Atherosclerosis of Monkeys

From the Department of Pathology (Comparative Medicine), Wake Forest University School of Medicine, Winston-Salem, North Carolina; and the Department of Exercise and Movement Sciences, William Paterson University, Wayne, New Jersey.

Address reprint requests to: Michael R. Adams, DVM Department of Pathology Wake Forest University School of Medicine Medical Center Boulevard Winston-Salem, NC 27157 E-mail: madams{at}wfubmc.edu

Objective: To determine the separate and combined effects of the estrogen and progestin components of a modern triphasic oral contraceptive (OC) formulation on extent of coronary artery atherosclerosis.

Methods: Female cynomolgus monkeys (n = 81) were fed atherogenic diets for 32 months. After the first 7 months, they were randomized to four groups and treated triphasically for 21 of each 28 days with ethinyl estradiol (E2) (monkey equivalent of 30–40 µg), levonorgestrel (monkey equivalent of 50–125 µg), a combination of the two steroids, or placebo.

Results: Treatment with estrogen alone reduced coronary artery atherosclerosis extent 67% compared with untreated controls (P < .05). Treatment with progestin alone had no effect (P > .20). While atherosclerosis extent in monkeys treated with the combined OC was reduced 28%, this did not differ statistically from the other groups (P > .20).

Conclusion: In doses used for oral contraception, E2, like all other estrogens studied to date, has a marked inhibitory effect on atherosclerosis progression. Levonorgestrel, at doses used in modern OC formulations, antagonizes this effect. When considered with other experimental evidence, these findings support the concept that progestins used in OCs and hormone replacement therapy can antagonize estrogen’s atheroinhibitory effects. Whether this occurs seems to depend on a relative balance between estrogen and progestin with respect to dose, potency, route, and pattern of administration. However, when considered with evidence from previous studies, the findings also indicate a modest atheroinhibitory influence of combination (estrogenprogestin) OCs.

This article has been cited by other articles:

				R. K. Hermsmeyer, R. G. Mishra, D. Pavcnik, B. Uchida, M. K. Axthelm, F. Z. Stanczyk, K. A. Burry, D. R. Illingworth, J. C. Kaski, and F. J. Nordt Prevention of Coronary Hyperreactivity in Preatherogenic Menopausal Rhesus Monkeys by Transdermal Progesterone Arterioscler. Thromb. Vasc. Biol., May 1, 2004; 24(5): 955 - 961. [Abstract] [Full Text]

				J. B. Hodgin and N. Maeda Minireview: Estrogen and Mouse Models of Atherosclerosis Endocrinology, December 1, 2002; 143(12): 4495 - 4501. [Abstract] [Full Text] [PDF]